Abstract. We investigated the effects of YC-1, an activator of soluble guanylyl cyclase (sGC), on voltage-dependent K + (Kv) channels in smooth muscle cells from freshly isolated rabbit coronary arteries by using the whole-cell patch clamp technique. YC-1 inhibited the Kv current in a dose-dependent fashion with an apparent K d of 9.67 μ M. It accelerated the decay rate of Kv channel inactivation without altering the kinetics of current activation. The rate constants of association and dissociation for YC-1 were 0.36 ± 0.01 μ M , respectively. YC-1 did not have a significant effect on the steady-state activation and inactivation curves. The recovery time constant from inactivation was decreased in the presence of YC-1, and application of train pulses (1 or 2 Hz) caused a progressive increase in the YC-1 blockade, indicating that YC-1-induced inhibition of Kv currents is use-dependent. Pretreatment with Bay 41-2272 (also a sGC activator), ODQ (a sGC inhibitor), or Rp-8-Br-PET-cGMPs (a protein kinase G inhibitor) did not affect the basal Kv current and also did not significantly alter the inhibitory effect of YC-1. From these results, we suggest that YC-1 directly inhibits the Kv current independently of sGC activation and in a state-, time-, and use-dependent fashion.
Introduction
Guanylyl cyclases catalyze the conversion of guanosine triphosphate (GTP) to guanosine 3′5′-cyclic monophosphate (cyclic GMP), which has been regarded as an important signaling molecule in various cells and tissues. Guanylyl cyclases occur in both membrane-bound and soluble forms (1) . While the membrane-bound guanylyl cyclase is activated by extracellular agonists, soluble guanylyl cyclase (sGC) contains a prosthetic heme group and acts as an important intracellular receptor for nitric oxide (NO) (2) . In vascular smooth muscle, sGC is the predominant intracellular NO receptor, and the physiological actions of NO occur via the activation of sGC (3) .
YC-1, a cell-permeable derivative of benzylindazole, is a potent activator of sGC in various cells (4) . It increases the activity of purified sGC by approximately 10 times, independent of NO (5, 6) . In the vascular system, YC-1-induced activation of sGC increases levels of cGMP, which subsequently induces vascular relaxation YC-1 Inhibits Kv Channels by activating the Ca 2+ -activated K + (BK Ca ) channel (5, 7, 8) . Therefore, YC-1 is a very useful tool for studying the guanylyl cyclase / cGMP signaling pathway in vascular systems, but its undesired effects on other targets limit its usefulness in native cell systems.
Voltage-dependent K + (Kv) channels expressed in vascular smooth muscle participate in regulating membrane potential (9, 10) . Inhibition of the Kv channels by 4-aminopyridine causes the depolarization and vasoconstriction in various arteries (11, 12) . Given the usefulness of YC-1 and the physiological importance of Kv channels in the vascular system, a thorough understanding of all of the actions of YC-1 on Kv channels is essential for the accurate interpretation of experimental results obtained using this substance. Therefore, in the present study, we investigated the effect of YC-1 on Kv channels in freshly isolated coronary arterial smooth muscle cells. Our major finding was that YC-1 directly inhibits Kv channels in a state-, time-, and use-dependent fashion, that is completely independent of sGC activity.
Materials and Methods

Cell isolation
New Zealand White rabbits (2.1 -2.4 kg) of either sex were anaesthetized with sodium pentobarbitone (50 mg/ kg) and were injected simultaneously with heparin (100 U/kg) into the ear vein. The left descending coronary arteries were isolated and cleaned of the adventitia and endothelium in the normal Tyrode solution. The arteries were transferred to Ca 2+ -free normal Tyrode solution for 20 min and then incubated in the Ca 2+ -free normal Tyrode solution containing papain (1 mg/ml), dithiothreitol (DTT, 1.5 mg/ml), and bovine serum albumin (BSA, 1.5 mg/ml) for 25 min. The arteries were further incubated in the Ca 2+ -free solution containing collagenase (2.8 mg/ ml, 191 units/mg; Wako, Osaka), 1.5 mg/ml DTT, and 1.5 mg/ml BSA for 20 min. Single smooth muscle cells were obtained by gentle agitation with a Pasteur pipette in Kraft-Brühe (KB) solution, stored in the refrigerator, and used on the day of preparation.
Solutions and chemicals
The normal Tyrode solution contained 143 mM NaCl, 5.4 mM KCl, 0.33 mM NaH 2 PO 4 , 0.5 mM MgCl 2 , 1.8 mM CaCl 2 , 5.0 mM HEPES, and 16.6 mM glucose, adjusted with NaOH to pH 7.4. The KB solution contained 70 mM KOH, 50 mM L-glutamate, 55 mM KCl, 20 mM taurine, 20 mM KH 2 PO 4 , 3 mM MgCl 2 , 0.5 mM EGTA, 10 mM HEPES, and 16.6 mM glucose, adjusted with KOH to pH 7.3. The pipette solution contained 105 mM K-aspartate, 25 mM KCl, 5 mM NaCl, 1 mM MgCl 2 , 4 mM Mg-ATP, 10 mM BAPTA, and 10 mM HEPES, adjusted with KOH to pH 7.25. To minimize the activity of K ATP and Ca
2+
-activated currents, we included 4 mM Mg-ATP and 10 mM BAPTA in the pipette solution. In all experiments, the bath solution contained iberiotoxin (100 nM) to block the BK Ca channel. All pharmacological compounds were dissolved in distilled water or in dimethyl sulfoxide (DMSO) to make stock solutions, which were diluted in the normal Tyrode solution to the concentration used. The concentration of DMSO in the final solution was less than 0.1%, and we confirmed that this concentration of DMSO did not affect the currents that were recorded. YC-1, Bay 41-2272, 1 H - [1, 2, 4] oxadiazolol-[4,3-a ]quinoxalin-1-one (ODQ), and iberiotoxin was purchased from Sigma Chemical Co (St. Louis, MO, USA). Rp-8-Br-PET-cGMPs were purchased from Biolog Life Science Institute (Bremen, Germany).
Electrophysiology and data analyses
The whole cell currents were recorded from single smooth muscle cells using patch clamp technique. An Axonpatch-1C amplifier (Axon instruments, Union, CA, USA) and digital interface (NI-DAQ 7; National Instruments, Union, CA, USA) coupled to an IBM-compatible computer were used for patch clamp and data acquisitions. All experimental parameters were controlled using Patchpro software developed by our group. The patch pipettes were made from thin-walled borosilicate glass (Clark Electromedical Instruments, Pangbourne, UK) using a puller (pp-83; Narishige, Tokyo). We used patch pipettes with a resistance of 2 -3 M Ω , when filled with the pipette solutions.
Origin 6.0 software (Microcal Software, Inc., Northampton, MA, USA) was used for data analysis as described previously (13, 14) . A first-order blocking scheme was used to describe drug-channel interaction kinetics (15) . From this concept, the apparent affinity constant ( K d ) and Hill coefficient ( n ) were obtained by fitting concentration-dependence data to the following Hill equation:
The activation kinetics was calculated by fitting with a single exponential function, which was considered to be the dominant time constant of activation (13, 16) . The time courses of the current during inactivation were fitted to a single (control) or double exponential function (presence of YC-1). The apparent rate constants for binding ( k +1 ) and unbinding ( k −1 ) were obtained from the following equation: The experimental points were calculated as follows:
, where I max is the maximal current measured at the most hyperpolarized preconditioning pulse and I c is a nonzero current that was not inactivated. We subtracted this nonzero residual current from the actual values.
Activation curves were fitted with a Boltzmann distribution: y = 1 / {1 + exp (−( V − V 1/2 ) / k )} , where k = slope factor, V = test potential, and V 1/2 = voltage of half-maximal conductance. The steady-state inactivation data were studied by using a two-pulse protocol; currents were measured with a 300-ms-long test potential to +40 mV, and 8-s preconditioning pulses were varied from −80 to +30 mV stepped by 10 mV in the absence and presence of drugs. The resulting steady-state inactivation data were fitted with another Boltzmann equation:
where V = preconditioning potential, V 1/2 = potential of the half-inactivation point, and k = slope value.
Results are expressed as means ± S.E.M. Student's t -test was used for the test of significance ( P < 0.05).
Results
YC-1-induced inhibition of the Kv current in rabbit coronary arterial smooth muscle cells
We used whole-cell patch-clamp techniques to investigate the effect of YC-1 on Kv channels in smooth muscle cells from rabbit coronary arteries. Under control conditions, the Kv current was rapidly activated to its peak and then slowly and partially inactivated during depolarization above +20 mV (Fig. 1A) , as reported previously (10, 14) . Decaying outward tail currents were recorded upon repolarization to −40 mV. As shown in Fig. 1 , exposure to 10 μ M YC-1 inhibited the Kv current throughout the entire voltage range of activation. Inhibition occurred within 2 min of switching to YC-1-containing solution. Analysis of the peak and steadystate of the current-voltage ( I -V ) relationship for the Kv current in the absence and presence of YC-1 showed that YC-1 predominantly affected the steady-state Kv current rather than the peak current ( Fig. 1 : B and C). Washout partially reversed YC-1-induced inhibition (<50%, data not shown).
Concentration dependence of inhibition of Kv currents by YC-1
The concentration dependence of Kv channel inhibition by YC-1 is shown in 
Concentration dependence of the time course of Kv channel inhibition
We next examined the time course of Kv channel inhibition by YC-1. The activation process data were fit to a single exponential function. Under control conditions, the time constant for activation of the Kv current was 7.96 ± 0.44 ms (n = 5), elicited by 600-ms depolarizing pulses from a holding potential of −60 mV to +60 mV. The peak Kv current was measured within 80 ms of the pulse, and the steady-state Kv current was measured at the end of the pulses. * P < 0.05, compared to the control.
In the presence of 10 μ M YC-1, the time constant was 7.91 ± 0.37 ms (n = 5), indicating that YC-1 did not significantly alter the time course of activation.
In contrast to the activation process, YC-1 accelerated Kv current decay in a concentration-dependent fashion ( Fig. 2A) . Therefore, we fitted the data to a double exponential function and obtained two time constants. We assumed that the time constant of the faster component represented the development of a drug-induced blockade of the Kv current ( τ D ), and that the slow time constant represented the slow and partial process of inactivation, which was due to intrinsic inactivation (9, 17) . To determine the apparent association and dissociation rate constants ( k +1 and k −1 , respectively), we plotted the data shown in Fig. 2 as the reciprocal of the time constant for Kv current inhibition at +40 mV vs. drug concentration (Fig. 3) . Using this approach, we calculated a k +1 of 0.36 ± 0.01 μ M . On the basis of the first-order reaction between the drug and channel, the theoretically derived
was determined to be 9.56 ± 0.11 μ M in the presence of YC-1. This result is in good agreement with the K d value calculated by fitting the concentration-response curves (Fig. 2) .
Effect of YC-1 on steady-state activation and inactivation of Kv channels
The voltage-dependence of activation and steadystate inactivation was evaluated to investigate whether YC-1-induced inhibition of the Kv current was due to a shift of the activation or inactivation curve. Activation curves were obtained using the tail current by a typical two-pulse protocol and the data were fit to a Boltzmann function. As shown in Fig. 4A , application of 10 μ M YC-1 did not shift the steady-state activation curve. The half-maximal activation potential ( V 1/2 ) and slope value ( k ) were −11.50 ± 0.42 mV and 8.66 ± 0.37, respectively, for the control conditions and −12.15 ± 0.83 mV and 9.62 ± 0.73, respectively, in the presence of 10 μ M YC-1.
The steady-state inactivation kinetics of the Kv currents were also investigated in the absence and presence of 10 μ M YC-1. The currents were obtained using a conventional double-pulse protocol (test step to +40 mV after an 8-s conditioning pre-pulse at different voltages). The inactivation data were fit to another Boltzmann function. As shown in YC-1.
Use-dependent inhibition of Kv currents by YC-1
Typical recovery kinetics of Kv currents in the absence and presence of 10 μ M YC-1 are shown in Fig. 5 . The recovery process was measured using a double-pulse protocol as shown in Fig. 5A (inset) . The inter-pulse interval was varied from 20 ms to 7,000 ms. The data for recovery from inactivation in the absence or presence of 10 μ M YC-1 were fit to single exponential functions with recovery time constants of 890.49 ± 105.64 ms under control conditions and 1,515.31 ± 169.36 ms in the presence of YC-1. The slower recovery time constant might explain the use-dependent blockade of the Kv current by YC-1. In agreement with this prediction, Fig. 5B also shows the use-dependence of the YC-1-block of the Kv current. Application of 20 repeated depolarizing pulses of +40 mV at 1 and 2 Hz progressively decreased the peak amplitude in the presence of 10 μ M YC-1. Under control conditions, the peak amplitude of the Kv current measured at the final pulse showed a weak frequency dependence, decreasing by 11.62 ± 0.76% at a frequency of 1 Hz and by 25.34 ± 0.81% at a frequency of 2 Hz. In the presence of 10 μ M YC-1, however, the peak amplitude showed a relatively strong frequency dependence, decreasing by 32.46 ± 0.90% at 1 Hz and by 38.77 ± 0.39% at 2 Hz. These data strongly suggest that the inhibitory effect of YC-1 is frequency (use)-dependent.
Effects of an alternative activator of sGC and of inhibitors of sGC and protein kinase G (PKG) on YC-1-induced inhibition of the Kv current
To confirm that YC-1-induced inhibition of the Kv current was not a result of sGC activation, we used an alternative sGC activator, Bay 41-2272, which is a pyrzolopyridine derivative (Fig. 6A, left) with a holding potential of −60 mV at frequencies of 1 and 2 Hz. The peak amplitude of current obtained at two different frequencies was normalized by the peak amplitude of the current at the first pulse, and plotted against the pulse number (n = 4). * P < 0.05, compared to the control.
(10 μ M YC-1 alone: 55.34 ± 5.21%, YC-1 + Bay 41-2247: 58.92 ± 6.48% inhibition, respectively, Fig. 6B ). Furthermore, a specific inhibitor of sGC, ODQ (10 μ M), had no effect on the Kv current, and ODQ together with YC-1 reduced the Kv current by 58.66 ± 7.28% (Fig.  6A, center) , an amount not significantly different from that observed in the absence of ODQ (Fig. 6B) . We also confirmed that cGMP -PKG signaling mechanisms were not involved in the YC-1-induced inhibition of Kv currents by pretreating the cells with a specific inhibitor of PKG, Rp-8-Br-PET-cGMPs (Rp-cGMPs) (Fig. 6A,  right) . Rp-cGMP failed to inhibit the Kv current and did not affect YC-1-induced inhibition of the Kv current. The application of KT 5823, another PKG inhibitor, yielded a similar result (YC-1 + Rp-cGMP: 57.82 ± 6.11% and YC-1 + KT 5823: 60.05 ± 6.23% inhibition, Fig. 6B ). These results are strong evidence that YC-1 exerts its effect not via the sGC-PKG signaling pathway but by directly affecting Kv channels in coronary arterial smooth muscle cells.
Discussion
In this study, we investigated the effect of YC-1, a selective agonist of sGC and a blocker of hypoxiainducible factor 1 (HIF-1) (19), on Kv channel function in smooth muscle cells from rabbit coronary arteries. Our results clearly suggest that YC-1 inhibits Kv channels in a state-, time, and use-dependent fashion independent of its sGC-activating properties and that it does not significantly alter the voltage-dependent activation and inactivation curves.
Several lines of evidence suggest that YC-1 inhibits Kv currents by acting directly on Kv channels, rather than by activating guanylyl cyclase: 1) Generally, activation of guanylyl cyclase increases cGMP levels and subsequently activates PKG, which hyperpolarizes smooth muscle by activating K + channels (20) . However, we found that YC-1 reduced Kv-channel activity, suggesting that the inhibitory effect of YC-1 on Kv channel was not mediated by guanylyl cyclase; 2) the YC-1 concentration used here to inhibit the Kv current was lower than that needed for stimulation of guanylyl cyclase (4, 5); 3) Bay 41-2272, an sGC activator (18) that is structurally different from YC-1, had no effect on the Kv current; 4) pretreatment with sGC and PKG inhibitors do not alter Kv-channel activity or the inhibitory effect of YC-1; 5) the effect of YC-1 occurred rapidly, reaching steadystate inhibition within 2 min. This instantaneous effect of YC-1, and the short exposure time required to reach steady-state inhibition, cannot be explained simply by activation of guanylyl cyclase-related signal transduction mechanisms. Taken together, these results strongly suggest that YC-1 directly interacts with Kv channels to inhibit the Kv currents, independent of guanylyl cyclase.
Our results also suggest that YC-1 preferentially interacts with Kv channels that are in the open state. It accelerated the time course of the Kv current in a concentration-dependent fashion. Furthermore, it had little effect on the activation time course and had relatively little effect on the peak amplitude of the Kv current at the onset of depolarization. Finally, it did not shift the activation or steady-state inactivation curves, suggesting that it does not interact with Kv channels in their inactivated state but, instead, interacts with them in their open state.
Generally, four types of K + channels are present in vascular smooth muscle: ATP-sensitive K + (K ATP ), Ca channels, Kv channels plays a major role in determining the resting membrane potential and basal tone in some vascular smooth muscles (11, 12, 22) . Furthermore, Kv channels are actively regulated by agonist-induced protein kinase-dependent signaling pathways. For example, vasoconstrictor-induced inhibition of K + channels is attributed to the activation of phospholipase C and the subsequent activation of protein kinase C (PKC) (23 -26) . Vasodilator-induced activation of K + channels is caused by activation of adenylyl cyclase and/or guanylyl cyclase and the consequent activation of protein kinase A (PKA) and/or PKG (9, 20, 27 -30) . Therefore, several drugs are indispensable for the study of Kv-channel modulation by various agonist-mediated signaling pathways. However, some undesired effects of these drugs complicate the accurate interpretation of experimental data. In fact, previous studies have suggested that some protein kinase inhibitors directly block Kv currents, independently of their kinase-inhibiting activity. For example, the PKC inhibitor bisindolylmaleimide (I) directly blocks stably expressed Kv1.5 channels in Chinese hamster ovary (CHO) cells (13) and Kv channels from freshly isolated coronary and mesenteric arterial smooth muscle cells (14, 31) . Another PKC inhibitor, staurosporine, also blocks Kv1.3 channels stably expressed in CHO cells (32) and directly blocks the coronary Kv current (10). The PKA inhibitor H-89 blocks Kv channels in coronary smooth muscle cells (33) and Kv1.3 channels expressed in CHO cells (34) , independently of PKA inhibition. Furthermore, Kv3.1 and Kv1.5 channels stably expressed in CHO cells are inhibited by the protein tyrosine kinase inhibitors genistein and AG-1478, respectively (35, 36) . Here, we found convincing evidence that YC-1 directly inhibits Kv currents isolated from native coronary smooth muscle cells. These results might prove helpful in understanding the coronary vascular function related to cGMP-PKG signaling.
The Kv currents in vascular smooth muscle cells can be divided into the delayed rectifier current and transient current based on the different kinetics of activation and inactivation and the differences in pharmacological properties (9, 37) . The delayed rectifier Kv currents show slow activation and inactivation kinetics in comparison to the transient Kv currents (38, 39) . The Kv1.2, Kv1.5, and Kv2.1 α subunits were known to form the homotetrameric and heterotetrameric Kv channels with similar current kinetics to the native delayed rectifier Kv currents in vascular smooth muscle cells (40, 41) . The molecular identity of the delayed rectifier Kv channels in vascular smooth muscle cells still, however, remains to be defined. Although we do not have direct evidence about the Kv-channel subtype that is inhibited by YC-1, our data imply that YC-1 may inhibit Kv1.2, Kv1.5, and/ or Kv2.1 channel subunits in coronary arterial smooth muscle cells. Additional experiments need to be carried out to determine whether YC-1 inhibits Kv currents in HEK-293 cells transiently transfected with Kv1.2, Kv1.5, or Kv2.1 gene and whether inhibition of Kv1.5 (or Kv1.2 or Kv2.1) using siRNA can abolish the YC-1-mediated decrease in coronary arterial smooth muscle cells.
Several previous reports have suggested that the activation of the sGC-mediated increase in cGMP plays an important role in vasodilation by activation of BK Ca channels (42, 43) . Therefore, application of YC-1 could increase the K + efflux by activating BK Ca channels, although this conflicts with the observation that YC-1 induces Kv-channel inhibition. However, in our experimental conditions, the activation of BK Ca channels were minimized by the inclusion of 10 mM BAPTA, a Ca 2+ chelator, in the pipette solution and the pretreatment with iberiotoxin (100 nM), a specific BK Ca -channel inhibitor, in the bath solution. Also, it has been reported that agonist-mediated activation of BK Ca channels through cAMP and cGMP-dependent protein kinases could be inhibited with treatment of 100 nM iberiotoxin (43) . Therefore, we are confident that under our experimental conditions, there is a minimal contribution of BK Ca to the Kv currents.
In conclusion, we have demonstrated that YC-1 directly inhibits the Kv current of rabbit coronary arterial smooth muscle cells in a state-, time-, and use-dependent fashion and that these inhibitory effects are completely independent of sGC activity and HIF-1. Since YC-1 is one of the most widely used agents in sGC-PKG signal transduction research, acts as an HIF-1 inhibitor, and has anticancer activity, caution is needed in the design and interpretation of functional studies of vascular physiology using YC-1.
